These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 28540034)

  • 1. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.
    Dos Santos RG; Bouso JC; Hallak JEC
    Ther Adv Psychopharmacol; 2017 Apr; 7(4):141-157. PubMed ID: 28540034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services.
    Baker MR; O'Shea CI
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39142841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
    Cameron LP; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
    Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interactions involving classic psychedelics: A systematic review.
    Halman A; Kong G; Sarris J; Perkins D
    J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hallucinogenic world of tryptamines: an updated review.
    Araújo AM; Carvalho F; Bastos Mde L; Guedes de Pinho P; Carvalho M
    Arch Toxicol; 2015 Aug; 89(8):1151-73. PubMed ID: 25877327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
    Dos Santos RG; Hallak JEC
    Neurosci Biobehav Rev; 2020 Jan; 108():423-434. PubMed ID: 31809772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
    Cakic V; Potkonyak J; Marshall A
    Drug Alcohol Depend; 2010 Sep; 111(1-2):30-7. PubMed ID: 20570058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
    Gable RS
    Addiction; 2007 Jan; 102(1):24-34. PubMed ID: 17207120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS; Soria G; Tudela R; Artigas F; Celada P
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
    Heise CW; Brooks DE
    J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
    Hinkle JT; Graziosi M; Nayak SM; Yaden DB
    JAMA Psychiatry; 2024 Dec; 81(12):1225-1235. PubMed ID: 39230883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.
    Dos Santos RG; Osório FL; Crippa JA; Riba J; Zuardi AW; Hallak JE
    Ther Adv Psychopharmacol; 2016 Jun; 6(3):193-213. PubMed ID: 27354908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
    Rodrigues AV; Almeida FJ; Vieira-Coelho MA
    J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
    Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.